Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.23)
# 393
Out of 4,944 analysts
238
Total ratings
41.74%
Success rate
19.2%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $112 → $105 | $28.97 | +262.44% | 19 | Aug 6, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $42 → $46 | $42.64 | +7.88% | 3 | Aug 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $36.58 | -12.52% | 8 | Aug 6, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $112 → $120 | $48.17 | +149.12% | 20 | Jul 29, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.45 | +101.83% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $9.43 | +207.53% | 3 | Jul 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $74 | $33.51 | +120.83% | 1 | Jul 7, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $6.68 | +139.52% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $6.84 | +46.20% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $8.30 | +261.45% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $20.40 | +297.06% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.03 | +131.02% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $81.14 | +51.59% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $2.93 | +2,971.67% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.73 | +304.62% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $61.10 | +116.04% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $17.20 | +45.35% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $24.99 | +168.11% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $7.19 | +192.07% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $9.14 | +217.29% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.01 | +323.94% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.94 | +312.37% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $14.60 | +297.26% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $3.05 | +260.66% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $6.56 | +174.39% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $3.14 | +345.86% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.78 | +630.34% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.60 | +1,212.50% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.03 | +482.52% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $2.13 | +838.97% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.42 | +572.51% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.87 | +48,028.34% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $1.90 | +2,057.89% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.36 | +11,804.76% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.73 | +11,559.81% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.46 | +2,312.87% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.96 | +4,597.29% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.03 | +967.96% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.29 | +4,551.16% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.33 | +6,666.92% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.46 | +172,502.74% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.50 | +32,138.57% | 1 | Jan 9, 2020 |
Ultragenyx Pharmaceutical
Aug 6, 2025
Maintains: Overweight
Price Target: $112 → $105
Current: $28.97
Upside: +262.44%
Supernus Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $42 → $46
Current: $42.64
Upside: +7.88%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $36.58
Upside: -12.52%
PTC Therapeutics
Jul 29, 2025
Maintains: Overweight
Price Target: $112 → $120
Current: $48.17
Upside: +149.12%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.45
Upside: +101.83%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $9.43
Upside: +207.53%
Monopar Therapeutics
Jul 7, 2025
Initiates: Overweight
Price Target: $74
Current: $33.51
Upside: +120.83%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.68
Upside: +139.52%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $6.84
Upside: +46.20%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.30
Upside: +261.45%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $20.40
Upside: +297.06%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $3.03
Upside: +131.02%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $81.14
Upside: +51.59%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $2.93
Upside: +2,971.67%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.73
Upside: +304.62%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $61.10
Upside: +116.04%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $17.20
Upside: +45.35%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $24.99
Upside: +168.11%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $7.19
Upside: +192.07%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $9.14
Upside: +217.29%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.01
Upside: +323.94%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.94
Upside: +312.37%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.60
Upside: +297.26%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.05
Upside: +260.66%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $6.56
Upside: +174.39%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $3.14
Upside: +345.86%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.78
Upside: +630.34%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.60
Upside: +1,212.50%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.03
Upside: +482.52%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $2.13
Upside: +838.97%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.42
Upside: +572.51%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.87
Upside: +48,028.34%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $1.90
Upside: +2,057.89%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.36
Upside: +11,804.76%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.73
Upside: +11,559.81%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.46
Upside: +2,312.87%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $0.96
Upside: +4,597.29%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.03
Upside: +967.96%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.29
Upside: +4,551.16%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.33
Upside: +6,666.92%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.46
Upside: +172,502.74%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.50
Upside: +32,138.57%